- Abstract:
-
Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, but only ∼50% of patients respond. A response only manifests after many months of treatment and is transient. The reasons underlying AZA resistance are unknown, and few alternatives exist for non-res...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Publisher's version
- Files:
-
-
(pdf, 2.7mb)
-
- Publisher copy:
- 10.1016/j.celrep.2017.06.067
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
- Publisher:
- Cell Press Publisher's website
- Journal:
- Cell Reports Journal website
- Volume:
- 20
- Issue:
- 3
- Pages:
- 572-585
- Publication date:
- 2017-07-18
- DOI:
- ISSN:
-
2211-1247
- Pubs id:
-
pubs:709350
- URN:
-
uri:3ff95b3b-7a63-40de-a9e5-c7ea6efd67e4
- UUID:
-
uuid:3ff95b3b-7a63-40de-a9e5-c7ea6efd67e4
- Local pid:
- pubs:709350
- Language:
- English
- Keywords:
- Copyright holder:
- Unnikrishnan et al.
- Copyright date:
- 2017
- Notes:
-
Copyright © 2017 The Authors.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Journal article
Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes
Actions
Access Document
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Funding
National Health and Medical Research Council
More from this funder
Leukaemia Foundation
More from this funder
Anthony Rothe Foundation
More from this funder
Cancer Institute for New South Wales
More from this funder
South Eastern Area Laboratory Services
More from this funder
Expand funders...
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record